Hair Loss Clinical Trial
Official title:
Ocular Comorbidities of Alopecia Areata
Verified date | May 2017 |
Source | Assiut University |
Contact | Eman Riad, MD |
Phone | 00201005298992 |
E_raid[@]aun.edu.eg | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Alopecia areata (AA) is a common, idiopathic and sometimes recurrent non-scarring type of
hair loss.
Several etiological factors, including psychological, trauma-related, genetic and autoimmune
factors have been considered as possible etiological factors . A T cell-mediated autoimmune
mechanism in genetically vulnerable individuals is the most acceptable etiology.
Alopecia areata presents clinically with well demarcated patches of non cicatricial hair
loss in any hair bearing area with no remarkable gender preference.
Although AA may occur at any age, incidence is high among younger age groups. In fact, it is
the most common form of alopecia seen in children. Various clinical patterns of alopecia
have been described as patchy, diffuse, reticulate, ophiasis and ophiasis inversus.
Depending on the extent of hair loss, it can be classified into alopecia subtotalis,
alopecia totalis (complete loss of scalp hair), and alopecia universalis (complete loss of
body hair).
National Alopecia Areata Foundation has devised "Severity of Alopecia Tool Score" (SALT
score) as a measure of disease severity. Scalp is divided into 4 areas, namely, Vertex-40%
of scalp surface area; right and left profiles-18% each and posterior scalp aspect-24%. SALT
score is the sum of percentage of hair loss in the above mentioned areas.
Status | Not yet recruiting |
Enrollment | 1 |
Est. completion date | January 1, 2020 |
Est. primary completion date | July 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - patients of alopecia areata will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Exclusion Criteria: 1. Patients with documented eye disease. 2. Patients with any systemic illness. 3. Patients who received any systemic treatment with possible ocular implications in the last three months. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Ergin C, Acar M, Kaya Akis H, Gönül M, Gürdal C. Ocular findings in alopecia areata. Int J Dermatol. 2015 Nov;54(11):1315-8. doi: 10.1111/ijd.12897. Epub 2015 Jul 3. — View Citation
Esmer O, Karadag R, Cakici O, Bilgili SG, Demircan YT, Bayramlar H, Karadag AS. Ocular findings in patients with alopecia areata. Int J Dermatol. 2016 Jul;55(7):814-8. doi: 10.1111/ijd.13114. Epub 2016 Apr 7. — View Citation
Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermoscopy in alopecia areata: analysis of 300 cases. Int J Dermatol. 2008 Jul;47(7):688-93. doi: 10.1111/j.1365-4632.2008.03692.x. — View Citation
Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000 Apr;42(4):549-66; quiz 567-70. Review. — View Citation
Nischal KC, Khopkar U. Dermoscope. Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):300-3. Review. — View Citation
Pandhi D, Singal A, Gupta R, Das G. Ocular alterations in patients of alopecia areata. J Dermatol. 2009 May;36(5):262-8. doi: 10.1111/j.1346-8138.2009.00636.x. — View Citation
Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987 Mar;16(3 Pt 2):730-6. — View Citation
Recupero SM, Abdolrahimzadeh S, De Dominicis M, Mollo R, Carboni I, Rota L, Calvieri S. Ocular alterations in alopecia areata. Eye (Lond). 1999 Oct;13 ( Pt 5):643-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the number of patient with occular affection in alopecia areata | percentage | 2 years | |
Secondary | correlate dermoscopic finding with disease severity and ocular finding | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05019066 -
Oral Herbal Combination Formulation and Hair Growth in Women
|
N/A | |
Recruiting |
NCT05502796 -
Natural History and Pathogenesis of Alopecia in Children and Adults
|
||
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Terminated |
NCT03709563 -
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
|
N/A | |
Completed |
NCT06095739 -
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
|
N/A | |
Completed |
NCT03351322 -
ENERGI-F701 for Female Hair Loss Treatment
|
Phase 2 | |
Recruiting |
NCT06215469 -
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
|
N/A | |
Completed |
NCT05945979 -
Evaluation of the Efficacy of a New Supplement for Hair and Nails - in Vitro, Clinical, Subjective and Instrumental Study
|
N/A | |
Not yet recruiting |
NCT05484973 -
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
|
N/A | |
Recruiting |
NCT05319444 -
Cleansing Device for the Treatment of Scalp and Hair Conditions
|
N/A | |
Completed |
NCT06120933 -
A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health
|
N/A | |
Withdrawn |
NCT04379583 -
HairDx Analytical Validation Study
|
||
Recruiting |
NCT05970809 -
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
|
N/A | |
Completed |
NCT00947219 -
Treatment of Androgenic Alopecia in Males
|
N/A | |
Enrolling by invitation |
NCT06174441 -
The Effect of 24-week Dietary Intake of Food Supplements on Hair
|
N/A | |
Unknown status |
NCT02393040 -
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia
|
N/A | |
Completed |
NCT01016964 -
Treatment of Androgenetic Alopecia in Females, 12 Beam
|
N/A | |
Recruiting |
NCT06283316 -
Systemic Treatments for Alopecia Areata Registry
|
||
Completed |
NCT04249128 -
Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)
|
Phase 3 | |
Recruiting |
NCT06117293 -
Safety and Efficacy Evaluation of the Mosaic Ultra Device
|
N/A |